PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20845054-0 2011 Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor. Sorafenib 25-34 colony stimulating factor 3 Homo sapiens 78-115 27015562-3 2016 Multiplex assays performed on tumor material that survived and re-grew after [pemetrexed + sorafenib] exposure showed increased phosphorylation of ERBB1 and of NFkappaB and IkappaB; with reduced IkappaB and elevated G-CSF and KC protein levels. Sorafenib 91-100 colony stimulating factor 3 Homo sapiens 216-221 20845054-1 2011 We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF). Sorafenib 47-56 colony stimulating factor 3 Homo sapiens 123-160 20845054-1 2011 We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF). Sorafenib 47-56 colony stimulating factor 3 Homo sapiens 162-167 20845054-6 2011 New combination therapy with sorafenib and S-1 exerted a therapeutic effect and apparently decreased serum and urinary G-CSF levels, although the patient died of gastrointestinal perforation. Sorafenib 29-38 colony stimulating factor 3 Homo sapiens 119-124 20845054-7 2011 The use of combined sorafenib and S-1 may be worthy of consideration in the treatment of RCC producing G-CSF. Sorafenib 20-29 colony stimulating factor 3 Homo sapiens 103-108